PreOmics
Martinsried
About PreOmics
PreOmics develops and provides innovative tools for customers around the world for mass spectrometry (MS)-based proteomics using cutting-edge technologies to support researchers in their protein analysis needs. PreOmics is as a spin-off company from the proteomics research group of pioneer Matthias Mann at the Max-Planck Institute of Biochemistry. They at PreOmics develop and provide innovative technologies for mass spectrometry-based proteomics to make your research simply better. Their mission is to provide you with the best possible solutions and at the highest quality to achieve your results faster, easier and in a more robust manner than ever before.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 51 – 100
- Estimated revenue: $1K – $10K
- Total funding: $19.2M
- Funding stage: Early Stage Venture
- Last round: Series B (Jan 2022)
- Website: preomics.com
- Phone: +49-89-2314163-0
Industries & Categories
Analytics, Biotechnology, Productivity Tools
Social Profiles
Canonical: https://fsome.com/organization/preomics-70852 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.